NCT06305559View on ClinicalTrials.gov

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
LipidemiaCoronary Artery DiseasePlaque, Atherosclerotic
Interventions
DRUG

obicetrapib 10 mg + ezetimibe 10 mg FDC daily

Active treatment

OTHER

Placebo

Baseline lipid modifying therapy

Trial Locations (1)

33016

RECRUITING

NGMR, Hialeah

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY